Mineralys Therapeutics logo

Mineralys Therapeutics

MLYS | NASDAQ
Chart Builder DCF Calculator
$14.53
-$0.80 (-5.22%)
At close: Nov 16, 2026, 4:00 PM ET
$14.29
-$0.24 (-1.65%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.22%

Rating

Updated: Nov 16, 2026
30.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #783/1021 (Top 77%)

Key Statistics

Market Data

Market Cap $1.29B
1D Range
14.45 15.77
52W Range
14.45 44.26

Valuation (TTM)

PE -3.33
PB 2.55
EV/EBITDA -2.07

Valuation (NTM)

Forward PE N/A
Forward PEG -0.04
Price Target $29.00
Loading financial charts...

Profile

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage produ...

Sector Healthcare
Industry Biotechnology
Employees 76
IPO Date Feb 10, 2023
Fiscal Year January - December

Latest News

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

8 days ago · globenewswire.com

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

12 days ago · seekingalpha.com

Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript
Mineralys Therapeutics to Participate in Upcoming Investor Conferences

13 days ago · globenewswire.com

Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

19 days ago · globenewswire.com

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

20 days ago · globenewswire.com

Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

25 days ago · globenewswire.com

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

28 days ago · globenewswire.com

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

1 month ago · globenewswire.com

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Earnings

Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$29.00
Upside
+99.59%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.